APRE
Aprea Therapeutics, Inc.
$0.74
-0.03 (-3.64%)
At close · Jul 8
Market Cap
$9.01M
Shares
12,382,776
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$12.6M
+2.8%
FY2025
Diluted EPS
-$1.93
+17.9%
FY2025
Operating Cash Flow
-$12.89M
+4.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $6.17M | $7.04M | $9.36M | $7.63M | $16.4M | $23.9M | $37.88M | $20.95M | $14.19M | $13.39M | |
| $6.53M | $6.48M | $6.46M | $8.43M | $20.97M | $13.55M | $14.93M | $8.59M | $2.29M | $2.46M | |
| — | $21.72K | $22.32K | $7052 | $4403 | $12.83K | $28.83K | $11.13K | $8316 | $7932 | |
| $12.7M | $13.52M | $15.82M | $16.06M | $113.39M | $37.45M | $52.81M | $29.54M | $16.49M | $15.85M | |
| -$12.58M | -$13.23M | -$14.32M | -$15.47M | -$113.39M | -$37.45M | — | — | — | — | |
| $623.84K | $634.27K | $1.36M | $1.19M | $730.2K | $319.05K | -$667.6K | $1.48M | $961.13K | $662.13K | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$11.95M | -$12.6M | -$12.96M | -$14.29M | -$112.66M | -$37.13M | -$53.48M | -$28.06M | -$15.53M | -$15.19M | |
| -$11.95M | -$12.61M | -$12.97M | -$14.27M | -$112.93M | -$37.45M | -$51.98M | -$30.83M | -$16M | -$14.7M | |
| USD/shares | — | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 | -$93.40 | — | — |
| USD/shares | — | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 | -$93.40 | — | — |
| shares | — | 6.54M | 5.51M | 3.62M | 1.66M | 1.06M | 1.06M | 300.12K | 57.72K | 57.65K |
| shares | — | 6.54M | 5.51M | 3.62M | 1.66M | 1.06M | 1.06M | 300.12K | 57.72K | 57.65K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Biotechnology median 7.68×